Baseline Characteristics of the DISCOVER CKD Prospective Cohort

期刊论文
出版模式：

开放获取
发表日期：

2024年11月29日

查看全文

Carol Pollock,
Juan-Jesus Carrero,
Eiichiro Kanda,
Richard Ofori-Asenso,
Hungta Chen,
Juan Jose Garcia Sanchez,
Surendra Pentakota,
Roberto Pecoits-Filho,
Steven Fishbane,
Carolyn S. P. Lam,
Naoki Kashihara,
David C. Wheeler

摘要

Introduction

Real-world data from patients with chronic kidney disease (CKD) are limited, particularly regarding clinical management, treatment patterns and health-related quality of life (HRQoL) in the context of new therapies and updated standard of care guidelines.

Methods

DISCOVER CKD is an observational cohort study enrolling adult patients with CKD, defined by an International Classification of Diseases, 10th Revision code, or with two estimated glomerular filtration rate measures < 75 ml/min/1.73 m² recorded 91–730 days apart. We describe the demographics, baseline characteristics and patient-reported outcomes of patients enrolled in the prospective phase.

Results

Of 1052 patients (mean age 62.5 years; 36.9% female) enrolled from the USA, UK, Spain, Italy, Sweden and Japan, 727 (69.1%) had stage 2–3b CKD and 325 (30.9%) had stage 4–5 CKD. Overall, 72.4%, 43.0% and 37.5% of patients had histories of hypertension, diabetes and hyperlipidaemia, respectively. In total, 58.7% and 14.0% were receiving renin–angiotensin–aldosterone system inhibitors (RAASi) and sodium-glucose co-transporter 2 inhibitors (SGLT2i), respectively. Compared with patients with stage 2–3b CKD, patients with stage 4–5 CKD reported numerically greater symptom burden across all 11 symptoms measured, numerically worse HRQoL across all eight categories measured using the 36-item Short Form (SF-36) questionnaire, and numerically greater impairment at work across all four categories measured using the Work Productivity and Activity Impairment chronic kidney disease (WPAI-CKD) questionnaire. Compared with patients with stage 2–3b CKD, a higher proportion of patients with stage 4–5 CKD had anaemia, hyperkalaemia and oedema (49.8% vs. 16.9%, 21.8% vs. 8.4% and 17.5% vs. 9.5%, respectively).

Conclusions

These contemporary real-world data from six countries highlight the substantial symptom, medication and psychosocial burden associated with CKD, and continued gaps in treatment.

Graphical abstract available for this article.

Trial registration

ClinicalTrials.gov identifier, NCT04034992.

Graphical Abstract